VIATRIS INC. for VIATRIS INC
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 3 - Lower Drug Costs Now Act; Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs H.R. 2846 - Ensuring Access to Lower-Cost Medicines for Seniors Act; Generic drug quality and FDA oversight H.R. 5376 - Build Back Better Act; Part D Formulary Design and Generic Drug Tiering S. 4348 - the Food and Drug Administration Safety and Landmark Advancements Act of 2022 Biosimilar interchangeability Part D Formulary Design and Generic Drug Tiering; Electronic labeling of prescription drugs H.R. 7667 - the Food and Drug Amendments of 2022; H.R. 8239 - Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 2023, and for other purposes. FDA facility inspections Medicate incentives for biosimilar utilization Complex Generic Drug Approvals
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILL DENT | — |
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| PETER WALLACE | — |
| ANNE WILSON | — |
Budget/Appropriations BUD
Medicaid Rebate provision of the Bipartisan Budget Act of 2015
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILL DENT | — |
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| PETER WALLACE | — |
| ANNE WILSON | — |
Copyright/Patent/Trademark CPT
Issues related Inter Partes Review (IPR) process for biosimilars and generic drugs Patent Settlements S4417 - Patent Trial and Appeal Board (PTAB) Reform Act of 2022
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILL DENT | — |
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| PETER WALLACE | — |
| ANNE WILSON | — |
Trade (domestic/foreign) TRD
Trade issues related to generic medicines Pharmaceutical supply chain
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILL DENT | — |
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| PETER WALLACE | — |
Financial Institutions/Investments/Securities FIN
Policy related to corporate governance
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID MARIN | — |
Taxation/Internal Revenue Code TAX
Corporate Tax Policy
| Lobbyist | Covered position, as disclosed |
|---|---|
| WILL DENT | — |
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| PETER WALLACE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.